Company news: Janssen, Zeno Group

Share this article:
Janssen is reassuming ex-US marketing rights for its Caeylx/Doxil cancer treatment. Merck & Co. has marketed the drug abroad since 1996. That deal expires at the end of the year, and marketing rights for the drug will revert to Janssen subsidiary ALZA Corp. Janssen currently markets the product in the US, Japan and Israel under the Doxil brand.

Zeno Group named former Burson-Marsteller healthcare head Ame Wadler managing director for health and strategic planning. Wadler joins the firm from MWW Group, where she was EVP, chief management officer. Before that, she was chief strategic officer at Burson and chairman of the global healthcare practice, having joined that firm from Zeno Group parent Edelman.
Share this article:

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.